Publications by authors named "Lori J Wirth"

88Publications

Efficacy of Selpercatinib in -Altered Thyroid Cancers.

N Engl J Med 2020 08;383(9):825-835

From Massachusetts General Hospital (L.J.W.) and Dana-Farber Cancer Institute (J. Lorch), Boston; Memorial Sloan Kettering Cancer Center, New York (E.S., A.D.); Royal North Shore Hospital, St. Leonards, NSW (B.R.), and Peter MacCallum Cancer Institute, Melbourne, VIC (B.S.) - both in Australia; University of California, San Francisco-Helen Diller Family Comprehensive Cancer Center, San Francisco (H.K.), David Geffen School of Medicine at UCLA, Los Angeles (J.W.G.), and Chao Family Comprehensive Cancer Center, University of California Irvine, Orange (V.W.Z.) - all in California; University of Michigan, Ann Arbor (F.W.), and START Midwest, Grand Rapids (N.L.) - both in Michigan; University of Pennsylvania, Philadelphia (M.B.); University of Chicago, Chicago (J.P.); Gustave Roussy, Villejuif (S.L.), Institut Bergonié, Bordeaux (Y.G.), Aix Marseille University, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Early Phase Cancer Trial Center CLIP2, Hospital La Timone, Marseille (F.B.), Centre Léon Bérard, Lyon (C.D.L.F.), and Hôpital Européen Georges-Pompidou, Faculté de Médecine Paris-Descartes, Paris (J.M.) - all in France; Mayo Clinic-Rochester, Rochester, MN (J.C.M.); Winship Cancer Institute of Emory University, Atlanta (T.K.O.); National Cancer Center Singapore, Singapore (D.S.W.T.); University of Bern, Bern, and Cantonal Hospital of Lucerne, Lucerne - both in Switzerland (O.G.); University of North Carolina-Chapel Hill, Chapel Hill (J.W.); University of Wisconsin-Carbone Cancer Center, Madison (M.E.B.); British Columbia Cancer Agency, Vancouver, Canada (J. Laskin); Oregon Health and Science University, Portland (M.H.T.); Universitätsklinikum Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany (M.K.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); Johns Hopkins Kimmel Cancer Center, Washington, DC (B.L.); Fundación Jimenez Diaz, START-Madrid, Madrid (V.M.); Loxo Oncology, Stamford, CT (K.E., M.N., D.H., E.Y.Z., X.H., L.Y., J.K., S.M.R.); University of Texas M.D. Anderson Cancer Center, Houston (V.S., M.E.C.); and Ohio State University Comprehensive Cancer Center, Columbus (M.H.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2005651DOI Listing
August 2020

Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.

Mod Pathol 2020 Jul 31. Epub 2020 Jul 31.

Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0638-5DOI Listing
July 2020

Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Cancer Cytopathol 2020 Oct 18;128(10):693-703. Epub 2020 May 18.

Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.22288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541685PMC
October 2020

Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples.

Front Endocrinol (Lausanne) 2019 11;10:612. Epub 2019 Sep 11.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2019.00612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749016PMC
September 2019

Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:364-372. Epub 2019 May 17.

6 Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238315DOI Listing
January 2019

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

Eur J Cancer 2019 01 22;106:61-68. Epub 2018 Nov 22.

Los Angeles Biomedical Research Institute and Division of Endocrinology and Metabolism, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.10.002DOI Listing
January 2019

Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.

Authors:
Lori J Wirth

J Clin Endocrinol Metab 2019 05;104(5):1655-1657

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article/104/5/1655/5185197
Publisher Site
http://dx.doi.org/10.1210/jc.2018-02437DOI Listing
May 2019

Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions?

J Oncol Pract 2018 10;14(10):603-605

Massachusetts General Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00529DOI Listing
October 2018

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Cancer 2018 06 14;124(11):2365-2372. Epub 2018 Apr 14.

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31344DOI Listing
June 2018

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

J Clin Oncol 2017 Oct 17;35(29):3315-3321. Epub 2017 Aug 17.

Maria E. Cabanillas and Komal Shah, The University of Texas MD Anderson Cancer Center, Houston, TX; Jonas A. de Souza, University of Chicago Medical Center, Chicago, IL; Susan Geyer, University of South Florida, Tampa; Michael E. Menefee, Mayo Clinic Jacksonville, Jacksonville, FL; Lori J. Wirth, Massachusetts General Hospital, Boston, MA; Stephen V. Liu, MedStar Georgetown University Hospital; John Wright, National Cancer Institute, Washington, DC; and Manisha H. Shah, Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.0226
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.0226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652872PMC
October 2017

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Cancer 2017 Jul 21;123(14):2642-2650. Epub 2017 Feb 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30541DOI Listing
July 2017

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Endocrine 2017 Apr 3;56(1):121-128. Epub 2017 Feb 3.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-017-1233-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368192PMC
April 2017

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

J Clin Oncol 2017 04 1;35(12):1341-1367. Epub 2017 Feb 1.

Harold J. Burstein and Steven G. DuBois, Dana-Farber Cancer Institute; Rebecca A. Miksad and Nadine Tung, Beth Israel Deaconess Medical Center; Lori J. Wirth and Don S. Dizon, Massachusetts General Hospital, Boston, MA; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria; Jeanny B. Aragon-Ching, Inova Schar Cancer Institute, Fairfax, VA; E. Gabriela Chiorean, University of Washington, Seattle, WA; Warren Allen Chow, City of Hope, Duarte, CA; John Frederick De Groot and John Heymach, University of Texas MD Anderson Cancer Center, Houston, TX; Steven Michael Devine, Ohio State University, Columbus; Nathan A. Pennell, Cleveland Clinic, Cleveland, OH; Wafik S. El-Deiry, Fox Chase Cancer Center; Joshua Adam Jones, University of Pennsylvania Health Systems; Lynn Mara Schuchter, University of Pennsylvania, Philadelphia, PA; Andrew S. Epstein, Memorial Sloan Kettering Cancer Center, New York, NY; Deborah K. Mayer, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Karen Marie Winkfield, Wake Forest Baptist Medical Center, Winston-Salem, NC; Michael S. Sabel, University of Michigan, Ann Arbor, MI; and Nancy N. Baxter, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5292DOI Listing
April 2017

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.

J Clin Endocrinol Metab 2016 11 22;101(11):4103-4109. Epub 2016 Aug 22.

Kolling Institute of Medical Research (B.R.), University of Sydney, New South Wales 2006, Australia; Department of Nuclear Medicine and Endocrine Oncology (M.S.), Gustave Roussy and University Paris-Sud, 94805 Villejuif, France; Department of Medicine (L.J.W.), Massachusetts General Hospital, Boston, Massachusetts 02114; Eisai Inc (C.E.D., J.S.), Woodcliff Lake, New Jersey 07677; Knight Cancer Institute (M.H.T.), Oregon Health and Science University, Portland, Oregon 97239; Department of Oncology (S.-B.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, 138-736, Republic of South Korea; Division of Medical Oncology and Hematology (M.K.K.), Princess Margaret Cancer Centre, Toronto, Ontario, Canada M5G 2M9; Department of Medical Oncology (J.C.), Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology, 08035 Barcelona, Spain; Department of Endocrine Neoplasia and Hormonal Disorders (S.I.S.), Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; and Department of Head and Neck Medical Oncology (M.T.), National Cancer Center Hospital East, Kashiwa 277-8577, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2015-3989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095235PMC
November 2016

ROS1 Rearrangement in Thyroid Cancer.

Thyroid 2016 06;26(6):794-7

1 Department of Pathology, Massachusetts General Hospital/Harvard Medical School , Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2016.0101DOI Listing
June 2016

Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.

Authors:
Lori J Wirth

J Clin Oncol 2016 Apr 16;34(12):1289-91. Epub 2016 Feb 16.

Massachusetts General Hospital, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.1414DOI Listing
April 2016

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

Clin Cancer Res 2015 Dec;21(24):5640-1

Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2298DOI Listing
December 2015

New and emerging therapeutic options for thyroid carcinoma: A&A discussion.

Clin Adv Hematol Oncol 2015 Apr;13(4 Suppl 4):17

Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
April 2015

Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.

Authors:
Lori J Wirth

Clin Adv Hematol Oncol 2015 Apr;13(4 Suppl 4):9-16

Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
April 2015

DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Semin Radiat Oncol 2015 Oct 14;25(4):237-50. Epub 2015 May 14.

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semradonc.2015.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575410PMC
October 2015

Lenvatinib in radioiodine-refractory thyroid cancer.

N Engl J Med 2015 05;372(19):1868

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1503150DOI Listing
May 2015

New frontiers and treatment paradigms for thyroid carcinoma.

Clin Adv Hematol Oncol 2014 Jul;12(7 Suppl 14):3-21; quiz 22

The University of Texas, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
July 2014

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.

Clin Cancer Res 2015 Mar 30;21(5):1028-35. Epub 2014 Dec 30.

Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2915DOI Listing
March 2015

Thyroid carcinoma, version 2.2014.

J Natl Compr Canc Netw 2014 Dec;12(12):1671-80; quiz 1680

From Memorial Sloan Kettering Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; University of Michigan Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Huntsman Cancer Institute at the University of Utah; Stanford Cancer Institute; City of Hope Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Roswell Park Cancer Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute; Duke Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0169DOI Listing
December 2014

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Lung Cancer 2014 Nov 27;86(2):241-6. Epub 2014 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293119PMC
November 2014

Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.

Authors:
Lori J Wirth

Cancer Prev Res (Phila) 2014 Mar 17;7(3):279-82. Epub 2014 Jan 17.

Massachusetts General Hospital, 55 Fruit Street, Yawkey 7B, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-13-0437DOI Listing
March 2014

Long-term survival after distant metastasis in patients with oropharyngeal cancer.

Oral Oncol 2014 Mar 31;50(3):208-12. Epub 2013 Dec 31.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2013.10.020DOI Listing
March 2014

Cabozantinib in progressive medullary thyroid cancer.

J Clin Oncol 2013 Oct 3;31(29):3639-46. Epub 2013 Sep 3.

Rossella Elisei, University of Pisa, Pisa; Lisa Licitra, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico-Istituto Nazionale dei Tumori, Milan, Italy; Martin J. Schlumberger, Institut Gustave Roussy, University Paris-Sud, Villejuif, France; Stefan P. Müller, Universitatsklinikum Essen, Essen; Michael C. Kreissl, Universitätsklinikum Würzburg, Würzburg, Germany; Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Manisha H. Shah, Ohio State University Medical Center, Columbus, OH; Barbara Jarzab, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach, Gliwice, Poland; Viktor Medvedev, Medical Radiological Research Centre of the Russian Academy of Medical Sciences, Obninsk, Russia; Bruno Niederle, Medizinische Universität Wien, Wien, Austria; Ezra E.W. Cohen, University of Chicago, Chicago, IL; Lori J. Wirth, Massachusetts General Hospital, Boston, MA; Haythem Ali, Henry Ford Health System, Detroit, MI; Colin Hessel and Yifah Yaron, Exelixis, South San Francisco, CA; Douglas Ball and Barry Nelkin, Johns Hopkins University School of Medicine, Baltimore, MD; and Steven I. Sherman, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.4659DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813PMC
October 2013

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

Head Neck 2014 Aug 10;36(8):1181-8. Epub 2014 Mar 10.

Harvard Radiation Oncology Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.23430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096067PMC
August 2014

Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.

Cancer Prev Res (Phila) 2013 May;6(5):410-8

Chao Family Comprehensive Cancer Center, University of California Irvine, Bldg. 56, Route 81, 101 The City Drive Cancer Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-13-0004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730525PMC
May 2013

Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.

N Engl J Med 2013 Feb;368(7):664-73

Department of Medicine, Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc1210080DOI Listing
February 2013

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

Thyroid 2013 Apr;23(4):392-407

Department of Public Health Sciences, Penn State College of Medicine, Pennsylvania State University, Hershey, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2012.0520DOI Listing
April 2013

Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.

Anticancer Res 2012 May;32(5):1743-6

Harvard Radiation Oncology Program, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
May 2012

Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease.

J Clin Oncol 2011 Jul 23;29(19):2616-8. Epub 2011 May 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.34.0505DOI Listing
July 2011

Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.

Int J Radiat Oncol Biol Phys 2011 Aug 20;80(5):1405-11. Epub 2010 Dec 20.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2010.04.029DOI Listing
August 2011

Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.

Cancer 2010 Oct;116(20):4761-8

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25305DOI Listing
October 2010

Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

Proc Natl Acad Sci U S A 2009 Mar 11;106(9):3318-23. Epub 2009 Feb 11.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0813320106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651339PMC
March 2009

A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.

Cancer Prev Res (Phila) 2008 Oct;1(5):339-48

Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-07-0003DOI Listing
October 2008

Seeking alternative biological therapies: the future of targeted molecular treatment.

Oral Oncol 2009 Apr-May;45(4-5):447-53. Epub 2008 Nov 21.

Dana Farber Cancer Institute, 44 Binney Street, SW430, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2008.08.009DOI Listing
May 2010

Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?

Hematol Oncol Clin North Am 2008 Dec;22(6):1155-63, viii

Dana Farber Cancer Institute, SW430, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2008.08.004DOI Listing
December 2008

Motesanib diphosphate in progressive differentiated thyroid cancer.

N Engl J Med 2008 Jul;359(1):31-42

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M.D. Anderson Cancer Center, Houston 77230-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa075853DOI Listing
July 2008

Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.

Int J Radiat Oncol Biol Phys 2008 Nov 28;72(4):1110-8. Epub 2008 May 28.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.02.048DOI Listing
November 2008

Recent advances in combined modality therapy for locally advanced head and neck cancer.

Curr Cancer Drug Targets 2007 Nov;7(7):674-80

Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156800907782418329DOI Listing
November 2007

Glioblastoma in a patient with early-stage tonsil cancer.

J Clin Oncol 2007 Jul;25(19):2848-50

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.3530DOI Listing
July 2007

Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer.

Otolaryngol Head Neck Surg 2006 Jun;134(6):916-22

Department of Surgery/Division of Otolaryngology, at the Brigham and Women's Hospital and the Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otohns.2006.02.001DOI Listing
June 2006

Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.

Arch Otolaryngol Head Neck Surg 2006 May;132(5):526-31

Division of Otolaryngology, Department of Surgery, Brigham and Women's Hospital and the Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archotol.132.5.526DOI Listing
May 2006

Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.

Int J Radiat Oncol Biol Phys 2006 Jul 6;65(4):1036-44. Epub 2006 May 6.

Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2006.02.010DOI Listing
July 2006

Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.

Am J Clin Oncol 2006 Apr;29(2):153-7

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000203756.36866.17DOI Listing
April 2006

Cetuximab and radiotherapy for head and neck cancer.

N Engl J Med 2006 Feb;354(6):634-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe058306DOI Listing
February 2006

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

J Clin Oncol 2005 Oct 19;23(28):6976-81. Epub 2005 Sep 19.

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.4182DOI Listing
October 2005

Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer.

Laryngoscope 2004 Nov;114(11):1924-31

Division of Otolaryngology, Head and Neck Surgery, Brigham and Women's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mlg.0000147921.74110.eeDOI Listing
November 2004

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.

Lung Cancer 2004 May;44(2):213-20

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2003.11.016DOI Listing
May 2004

Progress and perspectives in chemoprevention of head and neck cancer.

Expert Rev Anticancer Ther 2003 Jun;3(3):339-55

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.3.3.339DOI Listing
June 2003